デフォルト表紙
市場調査レポート
商品コード
949544

前立腺肥大症(BPH)治療の市場:2019-2025年

Benign Prostatic Hyperplasia Treatment Market 2019-2025

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
前立腺肥大症(BPH)治療の市場:2019-2025年
出版日: 2020年06月08日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の前立腺肥大症(BPH)治療市場は、予測期間中に大幅なCAGRで成長すると推定されています。中年人口の間で前立腺肥大症(BPH)が頻発していることは、市場を促進しています。 BPHは、51~60歳の男性の約50%、および80歳以上の男性の90%に影響を及ぼします。さらに、市場成長を促進する主な要因として、経済成長と公共・政府の認識が挙げられます。米国の健康擁護団体と保健当局は、毎年9月に「全米前立腺健康月間」という前立腺健康啓発キャンペーンを実施して、良性前立腺肥大症に関連するリスクと治療について人々に教育しています。

当レポートでは、世界の前立腺肥大症(BPH)治療市場について調査分析し、市場概要、市場成長への影響要因、市場規模と予測、セグメント別の市場分析、地域・国別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要および考察

  • 調査範囲
  • アナリストの考察&現在の市場動向

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略分析
  • 主要企業分析
    • Allergan PLC
    • Eli Lilly and Company
    • Merck&Co.、Inc.
    • Lumenis, Ltd.
    • オリンパス株式会社
    • Karl Storz GmbH&Co.Kg

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の前立腺肥大症(BPH)治療市場:治療別
    • 薬物療法
    • 低侵襲手術
    • レーザー治療
    • その他(外科、人工尿道リフト、塞栓術)

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • その他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • Allergan, Inc.
  • Astellas Pharma, Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corp.
  • Camber Pharmaceuticals, Inc.
  • Coloplast A/S
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly &Co.
  • Endo International PLC
  • GlaxoSmithKline PLC
  • Karl Storz GmbH& Co.Kg
  • Lumenis, Ltd.
  • Merck & Co., Inc.
  • Nymox Pharmaceutical Corp.
  • オリンパス
  • Pfizer, Inc.
  • ProArc Medical, Ltd.
  • Sanofi S.A.
  • Sophiris Bio Corp.
  • Sun Pharmaceutical Industries, Ltd.
  • Synthon B.V.
  • Teva Pharmaceutical Industries, Ltd.
  • Urologix, Inc.
  • Veru, Inc.
図表

LIST OF TABLES

  • 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)

2. GLOBAL MEDICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)

  • 3. GLOBAL MINIMALLY INVASIVE PROCEDURE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL LASER THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL OTHER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 7. NORTH AMERICAN BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 8. NORTH AMERICAN BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 9. EUROPEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 10. EUROPEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 11. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 12. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 13. REST OF THE WORLD BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET SHARE BY TREATMENT, 2018 VS 2025 (%)
  • 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 3. US BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF THE WORLD BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
目次
Product Code: OMR2021863

Global Benign Prostatic Hyperplasia Treatment Market Size, Share & Trends Analysis Report, by Treatment (Medications {Alpha-blockers, 5 Alpha reductase inhibitor (ARIs), Phosphodiesterase-5 Enzyme Inhibitor, and Others}, Minimally Invasive Procedures {TURP, TUIP, TUMT, and TUNA}, Laser Therapy {Ablative procedures and Enucleation procedures}, and Others) and Forecast Period 2019-2025

The global benign prostatic hyperplasia treatment market is estimated to grow at a significant CAGR during the forecast period. The rising frequency of benign prostatic hyperplasia among middle-aged people is driving the market. BPH affects nearly 50% of men between the ages of 51-60 and 90% of men age above 80. Moreover, some crucial factors attributing to the positive growth of the market, that are economic growth and public & government awareness. The US health advocate and health authorities conduct prostate health awareness campaign the "National Prostate Health Month" every year in September, to educate the people about the risk and treatment that are associates with benign prostatic hyperplasia.

The global benign prostatic hyperplasia treatment market is segmented based on treatment type. Based on the treatment type, the market is segmented into medications, minimally invasive procedures, laser therapy, and others. Based on medications, it is segmented into alpha-blockers, 5 alpha-reductase inhibitors (ARIs), a phosphodiesterase-5 enzyme inhibitor, and others. Based on minimally invasive procedures, it is segmented into transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), and Transurethral Needle Ablation (TUNA). Based on laser therapy, it is segmented into ablative procedures and enucleation procedures.Based on geography, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and RoW.

The key players providing benign prostatic hyperplasia treatmentproducts include Allergan PLC, Eli Lilly, and Co., Merck & Co., Inc., Abbott Laboratories, Allergan, Inc., Astellas Pharma, Inc., Pfizer, Inc., Sanofi S.A., Karl Storz GmbH& Co.Kg, Lumenis,Ltd., Olympus Corporation, Boston Scientific Corp., and others. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale. For instance, in May 2019, Lumenis Ltd. launched MOSES for BPH procedures. This device optimizes holmium energy transmission using pulse modulation. This technology also added to Holmium Laser Enucleation of the Prostate (HoLEP)

Research Methodology

The market study of the global benign prostatic hyperplasia treatment market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Reports of companies involved in the market
  • Authentic public databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog

The report is intended for providers, suppliers, and distributors of benign prostatic hyperplasia treatment, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.

The Report Covers:

  • Comprehensive research methodology of the global benign prostatic hyperplasia treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global benign prostatic hyperplasia treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusions

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Allergan PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Eli Lilly and Company
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Merck & Co., Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Lumenis, Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Olympus Corp.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments
    • 3.3.6. Karl Storz GmbH& Co.Kg
      • 3.3.6.1. Overview
      • 3.3.6.2. Financial Analysis
      • 3.3.6.3. SWOT Analysis
      • 3.3.6.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Benign Prostatic Hyperplasia Treatment Marketby Treatment
    • 5.1.1. Medications
      • 5.1.1.1. Alpha-blockers
      • 5.1.1.2. 5 Alpha reductase inhibitor (ARIs)
      • 5.1.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 5.1.1.4. Others
    • 5.1.2. Minimally Invasive Procedures
      • 5.1.2.1. Transurethral Resection of the Prostate (TURP)
      • 5.1.2.2. Transurethral Incision of the Prostate (TUIP)
      • 5.1.2.3. Transurethral Microwave Thermotherapy (TUMT)
      • 5.1.2.4. Transurethral Needle Ablation (TUNA)
    • 5.1.3. Laser Therapy
      • 5.1.3.1. Ablative procedures
      • 5.1.3.2. Enucleation procedures
    • 5.1.4. Others (Surgery, Prothetic urethral lift, Embolization)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Allergan, Inc.
  • 7.3. Astellas Pharma, Inc.
  • 7.4. Boehringer Ingelheim GmbH
  • 7.5. Boston Scientific Corp.
  • 7.6. Camber Pharmaceuticals, Inc.
  • 7.7. Coloplast A/S
  • 7.8. Daiichi Sankyo Co., Ltd.
  • 7.9. Eli Lilly &Co.
  • 7.10. Endo International PLC
  • 7.11. GlaxoSmithKline PLC
  • 7.12. Karl Storz GmbH& Co.Kg
  • 7.13. Lumenis, Ltd.
  • 7.14. Merck & Co., Inc.
  • 7.15. Nymox Pharmaceutical Corp.
  • 7.16. Olympus Corp.
  • 7.17. Pfizer, Inc.
  • 7.18. ProArc Medical, Ltd.
  • 7.19. Sanofi S.A.
  • 7.20. Sophiris Bio Corp.
  • 7.21. Sun Pharmaceutical Industries, Ltd.
  • 7.22. Synthon B.V.
  • 7.23. Teva Pharmaceutical Industries, Ltd.
  • 7.24. Urologix, Inc.
  • 7.25. Veru, Inc.